Chapter 191 Three families divide Jin and large-scale production of genetic enhancement drugs!

After all, the meat is rotten in the pot called Daxia. What is the difference between being held by the state team and by private enterprises? Moreover, Xingtu Technology is not an ordinary enterprise.

Although Xingtu Technology is not a state-owned enterprise, its importance is more important than 99% of the state-owned enterprises in Daxia. At least if Xingtu Technology rebels, it will be enough to cause serious damage to Daxia.

Under such circumstances, it is naturally not a big problem to sell Zhongxin International, a chip production plant that is of little use to Daxia, to Xingtu Technology.

Of course, this is just Lin Feng’s guess. Lin Feng cannot guarantee what Da Xia’s opinions and decisions are.

All we can say is that Lin Feng will try to persuade the higher-ups to sell Zhongxin International to Lin Feng in exchange for the implementation of domestic 10-nanometer chip manufacturing technology.

So Lin Feng, who had a plan for his future work, began the preliminary preparations, but the world was unaware of Lin Feng's huge plan.

I believe that when the future knowledge inculcation technology and the virtual world that makes it impossible to distinguish between reality and falsehood come into being, the whole world will be shocked!
……

On the other hand, while Lin Feng was thinking about future development plans, there were new changes at the American Empire Broad Institute.

It turned out that the Broad Institute suffered a huge blow due to the human experiment some time ago, and the shareholders behind the scenes were also doing bad things.

In this case, the CRISPR/Cas9 gene editing technology patent and the 'Bode-001 AIDS specific drug' technology patent held by the Broad Institute.

All of them have been licensed for technical patents at low prices by world-renowned pharmaceutical companies such as Johnson & Johnson, Pfizer, Novartis, Roche, and Merck, resulting in multiple divisions in Shanxi.

In other words, from now on, Xingtu Genomics will not only face the Broad Institute, but also well-known companies such as Johnson & Johnson, Pfizer, and Novartis.

This has both advantages and disadvantages. The advantage is that the original fist is divided into multiple fingers, and after the R&D power and funds are dispersed, it will be more difficult for the West to develop its own genetic enhancement drugs.

The downside is that Western pharmaceutical companies are fighting on their own, and naturally they all end up choosing their own genetic medicine drug research and development projects.

This also means that Xingtu Gene Company will be in a situation where it will be fighting everywhere in the future, that is, in addition to the two diseases of hepatitis B and AIDS.

Other leukemia, hemophilia, tumors, cancer, rheumatoid arthritis, cystic fibrosis...

All diseases that can be treated using gene editing will be in contention.

This situation where a single company has to compete with the R&D progress of global pharmaceutical companies has put tremendous pressure on Xingtu Gene Company.

After all, a company's R&D funds and scientific researchers are limited, and the other party is a global pharmaceutical company, which naturally makes Xingtu Gene Company feel tremendous pressure.

However, because Lin Feng has developed an intelligence version of the gene enhancement drug, in the future, after the company's scientific researchers sign a more stringent contract, they will be injected with the intelligence version of the gene enhancement drug according to their contributions and levels.

Therefore, although the R&D funding and number of scientific researchers of Xingtu Gene Company are under tremendous pressure compared with global pharmaceutical companies, it has not reached a level that it cannot compete with.

As for which diseases will be launched first in the future, that is a matter for the future. With the foundation of Xingtu Gene Company, it will definitely occupy more than half of the market share.

Of course, in addition to the changes in the pharmaceutical industry, something happened overseas that made Xingtu Technology quite unhappy.

It turns out that the world's two largest graphics card manufacturers have increased the prices of graphics cards again because NVIDIA and AMD have increased the prices again, resulting in the second crazy price increase this year.

As for how much the price has increased?
Take the original ASUS GTX 980Ti graphics card as an example, its official price increased from 6750 yuan to 7550 yuan, a full 800 yuan increase, without any performance improvement. It can be said that NVIDIA and AMD are simply crazy!
After all, the current market situation requires a 20% to 30% increase in price to get a graphics card.

In other words, if consumers want to buy an ASUS GTX 980Ti graphics card, they will have to pay between 9040 summer yuan and 9785 summer yuan.

The price of this graphics card has gone crazy, and the whole world is wailing. Even netizens in many countries have called for an antitrust investigation into NVIDIA and AMD.

As for the effectiveness of their appeal?
All I can say is that those netizens are destined to waste their breath, because ordinary people don’t know the reason for the price increase of graphics cards. Don’t countries around the world know it either?
As for the appeals from the American people in their own country?

Their appeals have no effect at all!

Because we are now in the era of intelligent recommendation algorithm programs, every piece of news or information that appears in the eyes of users is determined by the program and is valuable.

Not to mention the second-generation Tik Tok recommendation algorithm program developed by Xingtu Technology, even the recommendation algorithm programs developed by Western companies themselves in the past one or two years.

That can all be done. You just need to set a keyword in the background so that your comments containing this keyword will not get any traffic recommendations at all.

So don't be fooled by the rising anger of global gamers, who are demanding an antitrust investigation into Nvidia and AMD.

But in reality, the relevant remarks did not make any splash at all overseas, and those game players only wasted their breath.

Of course, the rising prices of graphics cards have also made companies around the world jealous, and they all want to set up projects to develop graphics cards in order to get a piece of the pie.

In the meantime, as these technology companies publicly announced their moves, it naturally aroused the expectations of many gamers.

Of course, the players' expectations naturally include Xingtu Technology Company.

After all, Xingtu Technology spent a lot of money on the development of graphics cards, and I don’t know how the development progress of Xingtu Technology’s graphics cards is.

……

Time passed slowly, and in the blink of an eye, more than a month had passed, and it was November 2015, 11.

On this day, after such a long training, Lin Feng finally achieved the goal of teaching the artificial intelligence Jarvis how to formulate different types and versions of second-generation gene-enhancing drugs based on the differences in human genes.

This also means that from now on, Xingtu Gene Company can finally mass-produce various types and versions of second-generation gene-enhancing drugs, which can transform people into super gene warriors and high-IQ scientific researchers on a large scale.

When this news came out, not only Xingtu Gene Company and Xingtu Technology were shocked, but even Daxia was shocked.

Even the number one figure in Daxia called personally to commend Lin Feng, saying that Lin Feng's achievements were comparable to the role of a military region.

Needless to say, Lin Feng felt a little embarrassed by the praise.

After all, the great Mr. Qian is only said to be able to command five divisions, but his side was directly upgraded to a military region. Isn't this too exaggerated?

Of course, along with the praise from the number one person, the next thing is naturally the negotiation between the two sides. (End of this chapter)